Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett; Yves Boucher; Emmanuelle Di Tomaso; Dan G. Duda; Lance L. Munn; Ricky T. Tong; Daniel C. Chung; Dushyant V. Sahani; Sanjeeva P. Kalva; Sergey V. Kozin; Mari Mino; Kenneth S. Cohen; David T. Scadden; Alan C. Hartford; Alan J. Fischman; Jeffrey W. Clark; David P. Ryan; Andrew X. Zhu; Lawrence S. Blaszkowsky; Helen X. Chen; Paul C. Shellito; Gregory Y. Lauwers; Rakesh K. Jain

doi:10.1038/nm988

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle Di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. ChenPaul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain

Research output: Contribution to journal › Article › peer-review

1863 Scopus citations

Abstract

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

Original language	English (US)
Pages (from-to)	145-147
Number of pages	3
Journal	Nature Medicine
Volume	10
Issue number	2
DOIs	https://doi.org/10.1038/nm988
State	Published - Feb 2004

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm988

Cite this

Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S., Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., ... Jain, R. K. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10(2), 145-147. https://doi.org/10.1038/nm988

Willett, CG, Boucher, Y, Di Tomaso, E, Duda, DG, Munn, LL, Tong, RT, Chung, DC, Sahani, DV, Kalva, SP, Kozin, SV, Mino, M, Cohen, KS, Scadden, DT, Hartford, AC, Fischman, AJ, Clark, JW, Ryan, DP, Zhu, AX, Blaszkowsky, LS, Chen, HX, Shellito, PC, Lauwers, GY & Jain, RK 2004, 'Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer', Nature Medicine, vol. 10, no. 2, pp. 145-147. https://doi.org/10.1038/nm988

@article{93b960d094824e50a82c12b14aeff451,

title = "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer",

abstract = "The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.",

author = "Willett, \{Christopher G.\} and Yves Boucher and \{Di Tomaso\}, Emmanuelle and Duda, \{Dan G.\} and Munn, \{Lance L.\} and Tong, \{Ricky T.\} and Chung, \{Daniel C.\} and Sahani, \{Dushyant V.\} and Kalva, \{Sanjeeva P.\} and Kozin, \{Sergey V.\} and Mari Mino and Cohen, \{Kenneth S.\} and Scadden, \{David T.\} and Hartford, \{Alan C.\} and Fischman, \{Alan J.\} and Clark, \{Jeffrey W.\} and Ryan, \{David P.\} and Zhu, \{Andrew X.\} and Blaszkowsky, \{Lawrence S.\} and Chen, \{Helen X.\} and Shellito, \{Paul C.\} and Lauwers, \{Gregory Y.\} and Jain, \{Rakesh K.\}",

year = "2004",

month = feb,

doi = "10.1038/nm988",

language = "English (US)",

volume = "10",

pages = "145--147",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "2",

}

TY - JOUR

T1 - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

AU - Willett, Christopher G.

AU - Boucher, Yves

AU - Di Tomaso, Emmanuelle

AU - Duda, Dan G.

AU - Munn, Lance L.

AU - Tong, Ricky T.

AU - Chung, Daniel C.

AU - Sahani, Dushyant V.

AU - Kalva, Sanjeeva P.

AU - Kozin, Sergey V.

AU - Mino, Mari

AU - Cohen, Kenneth S.

AU - Scadden, David T.

AU - Hartford, Alan C.

AU - Fischman, Alan J.

AU - Clark, Jeffrey W.

AU - Ryan, David P.

AU - Zhu, Andrew X.

AU - Blaszkowsky, Lawrence S.

AU - Chen, Helen X.

AU - Shellito, Paul C.

AU - Lauwers, Gregory Y.

AU - Jain, Rakesh K.

PY - 2004/2

Y1 - 2004/2

N2 - The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

AB - The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

UR - https://www.scopus.com/pages/publications/11144354392

UR - https://www.scopus.com/inward/citedby.url?scp=11144354392&partnerID=8YFLogxK

U2 - 10.1038/nm988

DO - 10.1038/nm988

M3 - Article

C2 - 14745444

AN - SCOPUS:11144354392

SN - 1078-8956

VL - 10

SP - 145

EP - 147

JO - Nature Medicine

JF - Nature Medicine

IS - 2

ER -

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this